The right side of the scale depicts JMML pathogenesis with Shp2 mutants favoring uncontrolled leukemic cell growth. This is further promoted by the p110δ subunit of PI3K. The left side of the scale depicts the goal of targeted therapy in JMML. By blocking p110δ PI3K and by inhibiting MEK, hopefully the “scales of cell growth” will once again balance out.